The lancet oncology
-
The lancet oncology · Jan 2017
Comparative StudyPreleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Therapy-related myeloid neoplasms are secondary malignancies that are often fatal, but their risk factors are not well understood. Evidence suggests that individuals with clonal haemopoiesis have increased risk of developing haematological malignancies. We aimed to identify whether patients with cancer who have clonal haemopoiesis are at an increased risk of developing therapy-related myeloid neoplasms. ⋯ Cancer Prevention Research Institute of Texas, Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer, NIH through MD Anderson Cancer Center Support Grant, and the MD Anderson MDS & AML Moon Shots Program.
-
The lancet oncology · Jan 2017
Comparative StudyClonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
Clonal haemopoiesis of indeterminate potential (CHIP) is an age-associated genetic event linked to increased risk of primary haematological malignancies and increased all-cause mortality, but the prevalence of CHIP in patients who develop therapy-related myeloid neoplasms is unknown. We did this study to investigate whether chemotherapy-treated patients with cancer who have CHIP are at increased risk of developing therapy-related myeloid neoplasms. ⋯ Moffitt Cancer Center.